UK markets closed

Novo Nordisk A/S (NVO)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
131.54+1.55 (+1.19%)
At close: 04:00PM EDT
131.41 -0.13 (-0.10%)
After hours: 07:57PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close129.99
Open132.61
Bid131.36 x 1100
Ask132.38 x 900
Day's range131.30 - 133.50
52-week range77.96 - 148.15
Volume3,583,580
Avg. volume3,933,745
Market cap591.68B
Beta (5Y monthly)0.15
PE ratio (TTM)45.05
EPS (TTM)2.92
Earnings date07 Aug 2024
Forward dividend & yield1.37 (1.04%)
Ex-dividend date22 Mar 2024
1y target est147.80
  • Insider Monkey

    Novo Nordisk A/S (NVO): The Most Profitable Stock of the Last 20 Years According to Analysts?

    We recently compiled a list of the 20 Most Profitable Stocks of the Last 20 Years. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other profitable stocks. The stock market has a long history of generating wealth for investors. While past performance doesn’t guarantee […]

  • Benzinga

    Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval

    On Friday, China’s National Medical Products Administration (NMPA) approved Eli Lilly And Co (NYSE:LLY) Tirzepatide for long-term weight management. It is suitable for long-term weight management of adults whose body mass index (BMI) meets the following requirements based on diet control and increased exercise: ≥28 kg/m2 (obese) or ≥24 kg/m2 (overweight) with at least one condition. Tirzepatide is known in the U.S. as Mounjaro for diabetes and Zepbound for weight loss. Related: Chinese Generic O

  • Investor's Business Daily

    Is Eli Lilly Stock A Sell On A Rare Stumble In Obesity Treatment?

    Is Eli Lilly stock a buy after shares have leveraged a comeback following the acquisition of Morphic and positive weight-loss drug news?